Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 705564 in Systemic Lupus Erythematosus
NCT03771885Phase 1Withdrawn
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of BI 705564 in systemic lupus erythematosus (SLE) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Number of patients with drug related Adverse Events up to 73 Days. Planned start Mar 2019; status: withdrawn.
02
Drugs
BI 705564
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03771885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03771885.